SCIENTIFIC HUB

Araştırmanın izini sürün.

SCIENTIFIC LITERATURE · PPR

LRRK2 p.Gly2019'un başlangıcındaki yaşSer Parkinson hastalığı ancestriler ve menşei ülkeler arasında

The age at onset of LRRK2 p.Gly2019Ser Parkinson’s disease across ancestries and countries of origin

Makine çevirisi · Editoryal inceleme bekliyor

· 2025-06-09

DOI: 10.1101/2025.06.04.25327685

Erişim kaynaktan kontrol edilmeliPreprintKaynağa git ↗

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

Objectives The LRRK2 p.Gly2019Ser pathogenic variant has reduced penetrance and presents a wide range of age at onset (AAO) in patients with Parkinson’s disease (PD). We aim to elucidate differences in the cumulative incidence of LRRK2 p.Gly2019Ser - related PD ( LRRK2 -PD) between ancestries and countries. Methods We included N=922 unrelated LRRK2 p.Gly2019Ser variant carriers (affected: N=762, unaffected: N=160) from the Global Parkinson’s Genetics Program (GP2) in addition to cohorts recruited from the Israeli Ashkenazi Jewish and Tunisian Arab-Berber population. The p.Gly2019Ser variant was present in five ancestries: Ashkenazi Jewish (N=534), North African (N=223), European (N=132), Middle Eastern (N=19) and Latino and Indigenous people of the Americas (N=14). In addition to ancestry derived from the genetic data, we assessed the country of origin in our analysis. The Cox proportional-hazards model and Kaplan-Meier analysis were applied to examine differences in cumulative incidence. All analyses were adjusted for biological sex, and the outcome variable was AAO, including affected and unaffected variant carriers with right censoring for affection status, and all analysis were exploratory. Results The median AAO of LRRK2 -PD was five years younger in the North African (HR=1.48, 95% CI: 1.18-1.86, p=7.0×10 −4 ) compared to the European ancestry group. In contrast, the median AAO was five years older in the Ashkenazi Jewish (HR=0.61, 95% CI: 0.50-0.75, p=4.0×10 −6 ) compared to the European ancestry group. Additionally, patients from Israel (HR=1.59, 95% CI: 1.30-1.39, p=4.0×10 −6 ) and Tunisia (HR=2.57, 95% CI: 2.16-3.06, pDiscussion Our results provide evidence that a person’s genetic ancestry and country of origin are associated with the AAO of LRRK2 -PD. This highlights the potential impact of both genetic and environmental factors on LRRK2 -PD AAO.

Bilimsel değerlendirme

01

Araştırma sorusu

Sorunun kapsamı orijinal çalışma üzerinden değerlendirilir.

02

Yöntem ve örneklem

Çalışma tasarımı ve örneklem için kaynak makaleyi kontrol edin.

03

Temel bulgular

Bu kayıt için editoryal olarak onaylanmış bulgu özeti henüz yayımlanmadı.

04

Sınırlılıklar

Sonuçların genellenebilirliği, yanlılık ve klinik anlamı ayrıca incelenmelidir.

Bibliyografik veriden yöntem, örneklem veya klinik sonuç çıkarımı yapılmaz.